Healthcare Industry News: ExtraCorporeal Circulation
News Release - May 10, 2012
Sorin Group Announces FDA Approval and Commercial Launch of Complete Portfolio of Implantable Heart Device LeadsNew pacing, defibrillation and left ventricular leads, combined with Sorin Group’s innovative implantable devices enable effective management of arrhythmias and heart failure
BOSTON--(Healthcare Sales & Marketing Network)--Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today at Heart Rhythm 2012, the Heart Rhythm Society’s 33rd Annual Scientific Sessions, FDA approval and commercial launch for a full portfolio of pacing, defibrillation and left ventricular leads. Designed for effective electrical performance and durability, each of the three lead series – TILDA pacing leads, VIGILA defibrillation leads and CELERITY left ventricular leads – include multiple sizes and features to enable physicians to match their implant preferences with individual patient needs.
In addition to a flexible silicone lead body, steroid eluting tips that reduce inflammation, and iridium fractal coated electrodes with proven electrical performance1, each lead family offers its own additional features:
- TILDA pacing leads include a flexible lead body and distal tip and are designed for easy implantation and predictable performance.
- VIGILA defibrillation leads feature a symmetrical lead body and thick outer insulation. Convex shock coils embedded in silicone insulation are engineered to minimize tissue in-growth.
- CELERITY left ventricular leads have a flexible co-radial body, and are designed to facilitate access and ensure stability in targeted pacing sites regardless of patients’ coronary venous anatomies.
About Sorin Group
Sorin Group (www.sorin.com) is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, Sorin Group focuses on three major therapeutic areas: cardiopulmonary bypass (ExtraCorporeal Circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.
For more information, please visit www.sorin.com.
Source: Sorin Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.